DEMAND: Immediately Stop Distribution, Access and Administration of COVID-19

mRNA Nanoparticle Injections Across All Name the County Vaccination Facilities and
Seize Inventory

Attention: Sheriff John Smith, Deputy Sheriff Jane Doe

CC: (list friends, church members, family, mediam and attorneys who have given permission)

It is well-established that the FDA clinical trials for the ‘COVID-19 vaccines’ (hereafter referred
to as ‘COVID-19 nanoparticle injections’ or ‘mRNA nanoparticle injections’ or ‘COVID-19
injections’) were not designed to clinically and statistically demonstrate that the COVID-19
nanoparticle injections prevent infection, prevent transmission, or protect against disease,
hospitalizations, and death.1-7

FDA clinical trials, US government data, and real-world evidence have demonstrated that mRNA
nanoparticle injections cause clinically significant increases in mild-to-moderate disease, serious
diseases, disabilities, hospitalizations, and death within days, weeks and/or months of receiving
COVID-19 mRNA nanoparticle injections in formerly healthy infants, children, and adults.2,4,6-13,
79-81

The COVID-19 mRNA nanoparticle injections were administered to civilian adults and children
through unlawful human experimentation, specifically whereas the clinical safety risks were
known by the FDA to outweigh any potential clinical benefits and the COVID-19 injections were
administered without informed consent regarding;

• the composition and variability of the COVID-19 nanoparticle injections’ vials,

• the gene-editing mechanism of action of COVID-19 nanoparticle technologies, and
• the known harmful, permanently disabling and/or sometimes deadly clinical outcomes of
being injected with engineered COVID-19 nanoparticle technologies. 2,4, 9,14-55,82

This DEMAND is sent to the attention of “Sheriff John Doe and Deputy Sheriff Jane Smith,”
who are hereafter referred to individually and collectively as “COUNTY LAW
ENFORCEMENT.”
 WHEREAS the ‘COVID-19 vaccines’ contain engineered nanoparticle technologies per
the manufacturer’s product labeling, FDA submissions, US military contracts, peer-reviewed
publications, patents, and manufacturer’s websites;1-8,11,14,19-24,26,32-37,51 and,

WHEREAS Pfizer ignored and violated 21 USC laws for conducting safe and legal
experimentation on humans with the use of FDA-regulated products when Pfizer stated that the
formulations of their COVID-19 injections distributed to US adults and children varied by LOT
number, per Pfizer’s approved August 23, 2021, biological license application (BLA);4,11,15-
19
and,

WHEREAS Pfizer’s criminal experimentation on civilian adults and children with the use of
varying biotechnologies in their COVID-19 mRNA nanoparticle formulations by ‘vaccine’ LOT
number (with some lots known to inflict harm, ranging from serious diseases and disabilities to
death), combined with lots that are placebos (known to be harmless), was confirmed by a
scientific European analysis of 52 different Pfizer mRNA nanoparticle ‘vaccine’ LOTS,
administered to 4,026,575 persons who received 10,793,766 doses (an average of 2.7
injections/person) between December of 2020 and January of 2022;79-81and,

WHEREAS the FDA and ‘vaccine’ manufacturers (i.e. Pfizer) clinically established that the
COVID-19 injections would cause an unprecedented incidence of disease, permanent disabilities,
and death, when on October 22, 2020 (before the ‘COVID-19 vaccine rollout’) the FDA met
with the manufacturers and reviewed this ‘working list’ of harmful clinical outcomes caused by
the injections; nervous system disease(convulsions, seizures, Guillain-Barre syndrome
myelitis encephalitis, encephalopathy, encephalomyelitis, narcolepsy, cataplexy, meningitis,
meningoencephalitis acute demyelinating diseases), cardiac disease (acute myocardial
infarction myocarditis, pericarditis, stroke), blood and circulatory disease(disseminated
intravascular coagulation, thrombocytopenia, venous thromboembolism), musculoskeletal
disease (arthritis, joint pain), reproductive and pregnancy disorders (adverse pregnancy
outcomes, adverse birth outcomes), autoimmune disease (VAED, multisystem inflammatory
syndrome), and death;9 and,

WHEREAS 696,605 nervous system disorders, 539,299 musculoskeletal and connective

tissue disorders (92,942 pain in extremities), and 317,811 gastrointestinal disorders, 224,633
skin, hair and nail disorders, 190,720 respiratory and chest disorders, 178,353 female and
male reproductive system disorders (erectile dysfunction, infertility, heavy menstrual
bleeding), 167,382 victims developed bacterial, viral, or parasitic infections (24,9010
herpetic infections), 126,993 cardiac disorders, 100,970 blood and lymphatic system
disorders, 77,148 psychiatric disorders, 73,542 vascular disorders, 61,518 eye disorders, 47,038
ear and labyrinth disorders (15,833 tinnitus), 31,895 autoimmune disorders, 13,647 kidney and
urinary disorders, 3,711 cancers and benign cysts, 4,056 pregnancy complications (1,859
spontaneous abortion complications, 1,143 genetic disorders, and 3,814 deaths were
documented in an internal Pfizer document as of June 18, 2022;56 and,

WHEREAS 17,560 deaths, 83,092 hospitalizations, 116,479 urgent care visits,194,594 doctor
visits, 36,014 anaphylaxis/severe allergic reactions, 13,515 cardiac events/conditions, 17,076
permanent disabilities, and an additional 14,494 life threatening events have been reported into
the CDC’s VAERS database as of June 16,2023, with an estimated 100-fold underreporting
factor per a Harvard Pilgrim Healthcare Analysis commissioned by HHS;57-58 and,

WHEREAS more than one (1) million adverse events were reported in the VAERS database
(1,055,219) in the year 2021 from the COVID-19 injections, including; hospitalizations,
permanent disabilities, anaphylaxis, heart attacks, miscarriages, adult, child, and newborn deaths
which is more than ALL reported adverse events from ALL childhood and adult vaccines over the
past 20 years combined prior to the COVID-19 injection rollout (1990 -2020);57 and,

WHEREAS based on data from the Defense Medical Epidemiology Database (DMED), it was
reported that US military men and women experienced a 2,181% increase in
hypertension, 1,048% increase in nervous system disorders, a 894% increase in malignant
neoplasms of esophagus, a 680% increase in multiple sclerosis, a 624% increase in malignant
neoplasms of digestive organs, 551% increase in Guillain-Barre syndrome (paralysis), a 487%
increase in breast cancer, 487% increase in demyelinating disease (damage to the myelin sheath
protecting nerve fibers of the brain, optic nerve, and spinal cord), a 474% increase in malignant
neoplasms of thyroid and other endocrine glands, a 472% increase in female infertility, a 468%
increase in pulmonary embolism, a 452% increase in migraines, a 437% increase in ovarian
dysfunction, 369% increase in testicular cancer, and a 302% increase in tachycardia;10 and,

WHEREAS data collected by the Joint Artificial Intelligence Center (JAIC) of the U.S.
Department of Defense (DoD), demonstrated that among 5.6 million Medicare beneficiaries 65
years and older who received Pfizer’s or Moderna’s mRNA nanoparticle technology injections or
remained un-injected, 71% of COVID-19 cases occurred in fully-vaccinated seniors and 60% of
COVID-19 hospitalizations occurred in fully-vaccinated seniors as of August 7, 2021;59 and

WHEREAS data published by the CDC on June 15, 2023, demonstrated that in adults who were
fully vaccinated or fully-vaccinated and boosted, and who were formerly immunocompetent
(healthy) experienced an increased risk for hospitalization due to COVID-19;60 and,

WHEREAS more than 4 million Americans reported a Grade 3 adverse event (as defined as
‘unable to perform their daily functions’) and approximately 200,000 (2%) required admittance
to the emergency room or hospital after receiving a COVID-19 injection according to the CDC’s
V-Safe database of 10 million US residents who were early recipients of COVID-19 injections as
of July 31, 2022;61 and,

WHEREAS 403,396 Florida residents who were early recipients of COVID-19 injections,
167,005 (41.1%) reported a Grade 3 adverse event (unable to perform their daily functions) and
8,471 (2.1%) required admittance to the emergency room or hospital after receiving a COVID-19
injection per the CDC’s V-Safe database report as of July 31, 2022;61 and,

WHEREAS Florida Surgeon General Joseph Ladapo identified 16,406 cardiac deaths from
Florida’s disease repository (MERLIN), Florida State Health Online Tracking System
(FLSHOTS), and death records, in adult Florida residents within 25 weeks of a 1st or 2nd mRNA
nanoparticle injection; 3,417 of these cardiac deaths occurred within 28 days of a 1st or
2nd mRNA nanoparticle injection and none of these deaths were attributed to COVID-19
infection or a history of heart disease;62 and

WHEREAS a recent systematic review of 100 studies, including case-reports and case studies,
demonstrated that the average rate of myocarditis (a formerly rare disease among healthy adults
and children) is 1.62% post COVID-19 mRNA nanoparticle injection, as well as demonstrated a
clinically significant incidence of cardiomyopathy, pulmonary embolism (PE), and vaccine-
induced thrombotic thrombocytopenia post COVID-19 mRNA injection;63 and,

WHEREAS it is clinically established that the mRNA ‘spike proteins’ and ‘lipid’ nanoparticles
cross the barrier membranes of the cardiovascular, respiratory, reproductive, and central nervous
system (including the brain); causing inflammation that can result in disease, disability, and
death, per peer-reviewed publications and research & development Pfizer documents;52-55,64-
67
and

WHEREAS there were 195% excess mortality claims in the State of Florida made to Group Life
Insurance companies in July-September of 2021, during the time period when President Biden’s
previously announced COVID-19 vaccine mandate was to go into effect by July 4, 2021, for all
employed Americans;68-69 and,

WHEREAS the CDC recorded an excess of 492,851deaths in the United States in 2022, and an
excess of 64,375 deaths in the first 14 weeks (Q1) of 2023;70 and,

WHEREAS on November 20, 2020, Pfizer stated in writing that the risk-benefit ratio of
their COVID-19 mRNA nanoparticle injections were not favorable (unfavorable) for children 12
to 15 years of age, based on FDA submitted data from 100 injected children from their Phase 3
trial;2 and,

WHEREAS on June 10, 2021, the FDA Vaccine and Biological Products Advisory
Committee (VRBPAC) stated in writing that it would not be infeasible (it would
be impossible) to conduct a clinical trial that could clinically and statistically prove that any
vaccine could prevent SARS-CoV-2 infection and/or COVID-19 disease in pediatric populations
because teenagers, children, and infants rarely (if ever) become infected or present with
symptoms;16 and,

WHEREAS children who received two (2) COVID-19 injections are 1400% (15x) more
likely to die of any cause than unvaccinated children and children who received three (3)
COVID-19 injections are 4400% (45x) more likely to die of any cause than unvaccinated
children per UK Government data;13,71 and,

WHEREAS, COVID-19 mRNA nanoparticle injections induce anaphylaxis,

appendicitis, fevers of greater than 104 degrees Fahrenheit, seizures (with eye rolling),
convulsions, status epilepticus (seizures lasting more than 5 minutes and multiple seizures that
can lead to permanent brain damage), epilepsy, exanthema subitum (herpes induced fevers and
seizures), hypotonia (limp ‘lifeless-like baby syndrome’), permanent brain damage confirmed by
an EEG, and lissencephaly (genetic-induced brain malformation characterized by the absence of
convolutions/folds), per Pfizer’s June 15, 2022, FDA clinical trial data submission of 6 month
old babies through 4 year old toddlers; in which a subgroup of 370 toddlers (2 to 4 year old) only
21 toddlers (5%) made it to their 1-month study follow-up visit after receiving their 3rd COVID-
19 mRNA injection, and in a subgroup of 344 babies (6 to 23 months old) only 3 babies (1%)
made it to their 1-month study follow-up visit after receiving their 3rd injection of COVID-19
mRNA injection; reasons for discontinuing or withdrawing from the study included adverse
events, neurological dysfunctions, ICU admission, hospitalization, and death (but reasons for
discontinuation or withdrawal need not be noted by the investigator);14 and,

WHEREAS the engineered COVID-19 mRNA nanoparticles can cross the blood brain barrier
causing demyelinating disease (deterioration to the protective covering of nerve cells) including
permanent changes to nerve cell structures, nerve cell damage, and nerve cell death in the spinal
cord and brain leading to permanent brain and neurological disorders and diseases, such as
the 696,605 neurological disorders and diseases documented by Pfizer;53,55,56,65,67 and,

WHEREAS the engineered mRNA nanoparticles cross the biological barriers of the male
reproductive system accumulating in the testis and epididymis adversely affecting sexual health
in men, including; sperm quality, quantity, morphology, and motility, and affecting male
hormones causing reproductive organ dysfunction such as the 178,353 female and male
reproductive system disorders documented by Pfizer (including male erectile dysfunction,
infertility, and testicular pain); 53,56,67 and,

WHEREAS the engineered COVID-19 mRNA nanoparticles cross the biological barriers of the
female reproductive system accumulating in the ovaries, placenta, and uterus, causing
reproductive dysfunction including damage to eggs and follicle development, and adversely
affecting the health of women, unborn babies and newborn babies, as was demonstrated by
the 178,353 female and male reproductive system disorders and 4,056 pregnancy
complications (including heavy menstrual bleeding, irregular menstruation, spontaneous
abortions, and infertility); 53,56,67 and,

WHEREAS the engineered mRNA nanoparticle technologies in the COVID-19 injections

are classified as electromagnetic devices per Pfizer’s Operation Warp Speed
contract and Title 21 US Code 351(a)(2)(B), and the 2017 FDA Guidance on Drugs and
Devices;23,24,49 and,
 WHEREAS the engineered nanoparticle technologies in COVID-19 mRNA
injections are gene-editing technologies per Pfizer’s May 18, 2021 FDA-submitted biological
license application stating that the COVID-19 mRNA mechanism-of-action is through RNA
transcription (nucleoside substitutions) substituting the genetic material of human cells within
human bodies with foreign genetic material;4,25,28,29and,

WHEREAS the engineered nanoparticle technologies in COVID-19 mRNA

injections are gene-editing nanotechnologies that use cationic liposome technologies to alter
human DNA through RNA transfection; as has been described in Pfizer’s biological license
application (BLA), on Pfizer’s website, in Dr. Robert Malone and colleagues’ 1996 patent
“Delivery of Exogenous DNA Sequences in a Mammal” for cationic liposome technology; and
as is demonstrated in multiple scientific papers and Pfizer’s internal report of 1,143 genetic
diseases spontaneously reported post- COVID-19 mRNA nanoparticle injection; 4,25-51,56,72,73 and,

WHEREAS it is an established scientific fact that the engineered nanoparticle

technologies in the COVID-19 mRNA injections are gene-editing technologies with known and
uknown risks for; integrating non-human DNA into the human genome, transmission of foreign
DNA into the germline (genetic mutations passed from parent to child through sperm or egg),
passage foreign genes into sperm, embryo/fetal and perinatal toxicity, genotoxicity (DNA
damage that can lead to birth defects and diseases i.e. cancers), and the potential for horizontal
transmission (i.e., shedding) is further confirmed in a June 9, 2023 peer-reviewed publication in
the International Journal of Molecular Science;82 and,

WHEREAS the COVID-19 mRNA nanoparticle injections were NEVER proven to prevent
infection, disease, hospitalization or death, per Pfizer’s November 20, 2020, FDA submission, in
which Pfizer stated in writing that out of 18,198 human subjects originally injected with
BNT162b2, 11% or two-thousand and fifty-three (2,053) developed mild, moderate, or severe
COVID-19 disease within 2 months of the 1st or 2nd mRNA nanoparticle injection; 1-3 and

WHEREAS 19 (0.1%) deaths were reported by Pfizer within 3 days -142 days (less than 4
months) post- Pfizer mRNA nanoparticle injections in previously healthy human subjects per
Pfizer’s May 18, 2021, post-hoc analysis;4 and,

WHEREAS the rotovirus vaccine (RotaShield) was pulled off the US market in 1999 due to
five cases (0.05%) of respiratory infection among 10,054 pediatric vaccine recipients;75 and,
WHEREAS the manufacturers of the COVID-19 nanoparticle injections NEVER submitted
clinical trial evidence demonstrating clinically and statistically significant protection against;
infection, symptomatic illness, medically attended illness, including emergency department and
urgent care visits, or severe illness, including hospitalization and death, but did submit clinical
data demonstrating an increased risk of heart inflammation, vaccine-related enhanced respiratory
disease, and vaccine-related enhanced autoimmune diseases per Pfizer’s August 23, 2021 FDA
approval and Moderna’s January 30, 2022, FDA approval;20-22, 75 and,

WHEREAS the engineered nanoparticles in the COVID-19 injections are

nanotechnologies designed to force human cells to produce disease-causing pathogens known as
spike proteins, spike proteins that are established lab-made pathogens that cause disease,
disabilities, and death per dozens of scientific and clinical publications, abstracts, and patents as
well as Pfizer’s internal documents and website;4,19-22,26-67and,

WHEREAS the engineered nanoparticle technologies (aka vaccine nanotechnology) in

the COVID-19 mRNA injections are patented for use as a nanocarrier of an ‘agent of
biowarfare,’ per US Patent Number 9539210, VACCINE NANOTECHNOLOGY;76 and,

WHEREAS COVID-19 injections containing engineered mRNA nanoparticle technologies meet

the legal definition of biological weapons according to 18 USC 175, Ch. 10: BIOLOGICAL
WEAPONS which is a biological agent, toxin and/or delivery device for use other
than prophylactic (preventative), protective, bona fide research, or other peaceful
purpose;77 and,

WHEREAS, COVID-19 injections containing engineered mRNA nanoparticles meet the

exact criteria of weapons of mass destruction according to F.S.790.166;78 and

WHEREAS, a person who manufactures, possesses, sells, delivers, displays, uses,

attempts to use, or conspires to use, or who makes readily accessible to others a weapon of mass
destruction commits a felony of the first degree per F.S.790.166;78 and

On behalf of ____________, I am demanding that COUNTY LAW ENFORCMENT

issue a cease and desist to immediately stop distribution, promotion, access and administration
of COVID-19 mRNA nanoparticle injections to All NAME OF COUNTY Vaccination Facilities
by _____ and to seize their mRNA nanoparticle injections inventory by __________.
Vaccination facilities are defined as all entities including but not limited to, a business entity,
government entity, healthcare provider, educational institution, or individual within NAME OF
COUNTY, as defined in Florida Statutes Sec. 768.38.

Vaccination facilities and administrators who do not comply with the cease and desist and
immediate forfeit COVID mRNA nanoparticle injections inventory will be in violation of in
F.S.790.166 and may subject imprisonment and/or fines.

(CLOSING)

By: __________________________

2 Corinthians 10: 3-6

For though we live in the world, we do not wage war as the world does. The weapons we fight
with are not the weapons of the world. On the contrary, they have divine power to demolish
strongholds. We demolish arguments and every pretension that sets itself up against the
knowledge of God, and we take captive every thought to make it obedient to Christ. And we will
be ready to punish every act of disobedience, once your obedience is complete.

REFERENCES

1. Pfizer Inc., BioNTech, initial new drug (IND) application. “A PHASE 1/2/3, PLACEBO-
CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO
EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF
SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY
INDIVIDUALS.” PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) Protocol
C4591001; Apr 2020.

2. Gruber M. (Dir CBER/OVRR), Naik R., Smith M., Wollersheim S., Huang L., et al. Pfizer
Inc. on behalf of Pfizer and BioNTech; “Emergency Use Authorization (EUA) for an
Unapproved Product.” Review Memorandum; Nov
2020. https://www.fda.gov/media/144416/download
3. Polack F., Thomas S., Kitchin N., et al. for the C4591001 Clinical Trial Group; “Safety and
Efficacy of the BNT162b2 mRNA Covid-19 Vaccine” New Engl J Med; Dec 10, 2020;
383:2603-2615. https://www.nejm.org/doi/full/10.1056/nejmoa2034577

4. Naik Ramachandra, PhD, Review Committee Chair, DVRPA/OVRR. BioNTech

Manufacturing GmbH in partnership with Pfizer, Inc. “COMIRNATY (BNT162b2): Active
immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and
older” FDA Approval of the Biological License Application (BLA) for BNT162b2/COMIRNATY;
Submitted May 18, 2021. Reviewed November 8, 2021.
https://www.fda.gov/media/151733/download

5. Zaks Tal, ModernaTX, Inc. initial new drug (IND) application. “A Phase 3, Randomized,
Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and
Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older,
mRNA-1273-P301” Aug 20, 2020. https://covid19crc.org/wp-content/uploads/2020/09/mRNA-
1273-P301-Protocol-2020.pdf

6. Agnihothram Sudhakar, PhD, Review Committee Chair, DVRPA/OVRR. ModernaTX Inc.

“SPIKEVAX (mRNA-1273): Active immunization to prevent coronavirus disease 2019
(COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in
individuals 18 years of age and older” FDA Approval of the Biological License Application
(BLA) for COVID-19 Vaccine, mRNA; January 30, 2023.
https://www.fda.gov/media/155931/download

7. ModernaTX, Inc. “FDA Briefing Document Moderna COVID-19 Vaccine” Vaccines and
Related Biological Products Advisory Committee (VRBPAC) Meeting. Emergency Use
Authorization (EUA); December 17, 2020. https://www.fda.gov/media/144434/download

8. Pfizer, Inc., BioNTech. “Application for licensure of a booster dose for COMIRNATY
(COVID-19 Vaccine, mRNA). FDA Briefing Document” Vaccines and Related Biological
Products Advisory Committee (VRBPAC) Meeting. September 17,
2021. https://www.fda.gov/media/152176/download
9. Anderson Steven, PhD, MPP – Dir. Office of Biostats & Epidemiology, CBER.
“FDA/CBER Plans for Monitoring COVID-19 Vaccine Safety & Effectiveness Vaccines &
Related Biological Products Advisory Committee (VRBPAC) Meeting” October 22, 2020.
https://www.fda.gov/media/143557/download?fbclid=IwAR1SooRjTDuhBPqM4TiD3O7vYgX4
eAp3CCqB7SzCk04CMve_OzgtMNPfNkc

10. Senator Ron Johnson, Subcommittee on Investigations, Ranking Member. “United States
Senate Letter: The Honorable Lloyd J. Austin III” regarding the Defense Medical Epidemiology
Database (DMED); Feb 1, 2022. https://www.ronjohnson.senate.gov/services/files/FB6DDD42-
4755-4FDC-BEE9-50E402911E02

11. Wollersheim Susan, MD, Schwartz Ann, MD. Lee Lucia, MD; Team Leader
CRB1/DVRPA/OVRR Allende Maria MD; Chief, CRB1/DVRPA/OVRR, BioNTech
Manufacturing GmbH in partnership with Pfizer, Inc. “BLA Clinical Review
MEMORANDUM” Biological License Application (BLA); August 23, 2021.
https://www.fda.gov/media/152256/download

12. Shresrha N., Burke P., Nowacki., et al. “Effectiveness of the Coronavirus Disease 2019
Bivalent Vaccine.” Open Forum Infect Dis. April 19, 2023. (Cleveland Clinic)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234376/

13. Nafilyan V., Bermingham C., Ward IL., et al. “Risk of death following SARS-CoV-2
infection or COVID-19 vaccination in young people in England: a self-controlled case series
study” MedRxiv. March 23, 2022.
https://www.medrxiv.org/content/10.1101/2022.03.22.22272775v1

14. Pfizer-BioNTech COVID-19 Vaccine EUA Amendment for Use in Children 6 Months
Through 4 Years of Age. “EUA amendment request for Pfizer-BioNTech COVID-19 Vaccine
for use in children 6 months through 4 years of age.” VRBPAC Briefing Document. June 15,
2022. https://www.fda.gov/media/159195/download

15. U.S. Department of Health and Human Services Food and Drug Administration, Office of
the Commissioner, Office of the Chief Scientist, Office of Counterterrorism and Emerging
Threats. “Emergency Use Authorization of Medical Products and Related Authorities” Guidance
for Industry and Other Stakeholders; January 2017. https://www.fda.gov/media/97321/download
16. Vaccines and Related Biological Products Advisory Committee Meeting. Licensure and
Emergency Use Authorization of Vaccines to Prevent COVID-19 for Use in Pediatric
Populations” FDA Briefing Document;June 10, 2021.
https://www.fda.gov/media/149935/download

17. 21 USC Chapter 1, Subchapter D, Part 312, Subpart C, §312.42

https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-C/section-312.42

18. 21 USC Chapter 9, Subchapter V, Part A, § 355-1

https://uscode.house.gov/view.xhtml?req=(title:21%20section:355-1%20edition:prelim)

19. 21 USC 225.1Vpume 4, Subpart A. Current Good Manufacturing Practice. 225.1

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=225.1

20. COMIRNATY Prescribing Information. Purple Cap. Dilute. April 2023.

https://labeling.pfizer.com/ShowLabeling.aspx?id=15623

21. COMIRNATY Prescribing Information. Grey Cap. Do NOT dilute. April

2023.https://labeling.pfizer.com/ShowLabeling.aspx?id=16351

22. SPIKEVAX Prescribing Information. November

2022. https://www.fda.gov/media/155675/download

23. DEPARTMENT OF THE ARMY U.S. ARMY CONTRACTING COMMAND. “COVID-

19 PANDEMIC—LARGE SCALE VACCINE MANUFACTURING DEMONSTRATION”
RPP #: 20-11 Project Identifier: 2011-003. Statement of Work for Pfizer. July 21,
2020. https://www.hhs.gov/sites/default/files/pfizer-inc-covid-19-vaccine-contract.pdf

24. 21 U.S. Code § 351a2B - Adulterated drugs and devices, Chapter 9, Subchapter V, Part A
https://www.law.cornell.edu/uscode/text/21/351#:~:text=For%20purposes%20of%20paragraph
%20(a,the%20manufacturing%20of%20drugs%2C%20and

25. U.S. Department of Health and Human Services Food and Drug Administration Center for
Biologics Evaluation and Research. “Design and Analysis of Shedding Studies for Virus or
Bacteria-Based Gene Therapy and Oncolytic Products” Guidance for Industry; Aug 2015.
https://www.fda.gov/media/89036/download
26. Silver, Kate.“Shot of a Lifetime: How Pfizer Developed its Own Raw Materials to Ensure a
Steady Supply for the COVID-19 Vaccine” Pfizer Website visited June 27, 2023.
https://www.pfizer.com/news/articles/shot_of_a_lifetime_how_pfizer_developed_its_own_raw_
materials_to_ensure_a_steady_supply_for_the_covid_19_vaccine

27. ThermoFisher Scientific.“How Cationic Lipid Mediated Transfection

Works.” ThermoFisher Scientific Website visited June 27, 2023
https://www.thermofisher.com/us/en/home/references/gibco-cell-culture-basics/transfection-
basics/gene-delivery-technologies/cationic-lipid-mediated-delivery/how-cationic-lipid-mediated-
transfection-works.html

28. Berkman BE, Deputy Director, NHGI Bioethics Core. “SUBSTITUTION” NIH National
Human Genome Institute Website visited June 27, 2023. https://www.genome.gov/genetics-
glossary/Substitution#:~:text=Substitution%2C%20as%20related%20to%20genomics,with%20a
%20different%20amino%20acid

29. Ganguly P, PhD, Chief Communications Officer, Nucleus Genomics, NHGI Office of
Communications. “TRANSLATION” NIH National Human Genome Institute
Websitehttps://www.genome.gov/genetics-glossary/Translation

30. Katragadda, CS., Choudhury, KS, and Murthy, PN. “Nanoparticles as Non-Viral Gene
Delivery Vectors” IEEE Transactions on Nanobioscience. January 2008 6(4):319-30
https://www.researchgate.net/publication/journal/IEEE-transactions-on-nanobioscience-1558-
2639

31. Alden M, Falla FO, Yang D, et al. “Intracellular Reverse Transcription of Pfizer BioNTech
COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line” Curr. Issues Mol.
Biol. Feb 23, 2022, 44 (3),1115- 1126; https://doi.org/10.3390/cimb44030073

32. Pfizer Website. “Unlocking the Power of our Body’s Protein Factory” Pfizer Websitevisited
June 28, 2023. https://www.pfizer.com/news/behind-the-science/unlocking-power-our-bodys-
protein-factory
33. Pfizer Website. “Turning Your Body into Medicine Factories” Pfizer Website visited June
28, 2023. https://www.pfizer.com/news/behind-the-science/how-once-little-known-molecule-
disrupting-medicine

34. Tenchov R. “The therapeutic potential of nanotechnology beyond COVID-19” Publication

for the American Chemical Society (ACS). November 18, 2022.
https://www.cas.org/resources/cas-insights/drug-discovery/therapeutic-potential-
nanotechnology-covid-19

35. Williams K and Brant S. “Indigenous perspectives on the biodigital

convergence” AlterNative: An International Journal of Indigenous Peoples;Vol 18. Issue 1.
April 6, 2022. https://doi.org/10.1177/11771801221090748

36. Friedrichs S and Bowman D. “COVID-19 may become nanomedicine’s finest hour
yet” Nature Nanotechnology;Volume 16, Pages 362–364. April 14, 2021.
https://www.nature.com/articles/s41565-021-00901-8

37. Vahedifard F and Chakravathy K. “Nanomedicine for COVID-19: the role of

nanotechnology in the treatment and diagnosis of COVID-19” Emergent Mater. 4(1): 75–99; Feb
13 2021.https://pubmed.ncbi.nlm.nih.gov/33615140/

38. Pfizer Inc. Confidential. “Structural and Biophysical Characterization of SARS-CoV-2

Spike Glycoprotein (P2 S) as a Vaccine Antigen” Pfizer Parent Compound Number(s): PF-
0730204. Dec 27, 2020. https://phmpt.org/wp-content/uploads/2023/02/125742_S1_M4_4.2.1-
vr-vtr-10741.pdf

39. Nickl P, Hilal T, Olal D, et al. “A New Support Film for Cryo Electron Microscopy Protein
Structure Analysis Based on Covalently Functionalized Graphene” Small;Vol 19. Issue 8: Feb
2023. https://onlinelibrary.wiley.com/doi/epdf/10.1002/smll.202205932

40. ThermoFisher Scientific. “Cryo EM Sample Preparation with the Vitrobot

System:Reproducible vitrification of biological samples” ThermoFisher Scientific
Website visited June 28, 2023. https://www.thermofisher.com/us/en/home/electron-
microscopy/products/sample-preparation-equipment-em/vitrobot-system.html
41. Fertility Associates of Memphis.
https://www.fertilitymemphis.com/vitrification/#:~:text=The%20word%20“vitrification”%20co
mes%20from,into%20a%20glass%2Dlike%20structure.

42. Joshua A Lees, Jaoa M Dias, and Seungil Han. Discovery Sciences, Medicine Design, Pfizer
Worldwide Research and Development, Groton, CT 06340, U.S.A “Applications of Cryo-EM in
small molecule and biologics drug design” Biochem Soc Trans. 2021 Dec 17; 49(6): 2627–
2638. Published online 2021 Nov 23. doi: 10.1042/BST20210444.
https://portlandpress.com/biochemsoctrans/article/49/6/2627/230276/Applications-of-Cryo-EM-
in-small-molecule-and

43. CDC “Pfizer/BioNTech COVID-19 Vaccine: Storage and Handling” May 2, 2023. CDC
Website visited site on June 27, 2023. https://www.cdc.gov/vaccines/covid-19/info-by-
product/pfizer/downloads/storage-summary.pdf

44. Pallesen J, Wang N, McLellan J, et al. “Immunogenicity and structures of a rationally

designed prefusion MERS-CoV spike antigen” August 14, 2017. PNAS;114 (35) E7348-
E7357 https://doi.org/10.1073/pnas.1707304114

45. Graham B, McLellan J, et al. “6VSB:Prefusion 2019-nCoV spike glycoprotein with a single
receptor-binding domain up” (2020) Science 367: 1260-1263. Research Center for Structural
Biology (RCSB) Protein Data Bank (PDB) https://www.rcsb.org/structure/6VSB

46. Graham B, McLellan J, and Ward A. “PREFUSION CORONAVIRUS SPIKE PROTEINS

AND THEIR USE” US2020/06185A: Feb 27,
2020. https://patentimages.storage.googleapis.com/e9/1f/3a/c72f6a8603a3b5/US20200061185A
1.pdf

47. Arbeitman, C.R., Rojas, P., Ojeda-May, P. et al. The SARS-CoV-2 spike protein is
vulnerable to moderate electric fields. Nat Commun 12, 5407 (2021).
https://doi.org/10.1038/s41467-021-25478-7

48. Cross R. “Without these lipid shells, there would be no mRNA vaccines for COVID-19”
Chemical & Engineering News. March 6, 2021 | Volume 99, Issue 8;
https://cen.acs.org/pharmaceuticals/drug-delivery/Without-lipid-shells-mRNA-vaccines/99/i8
49. U.S. Department of Health and Human Services Food and Drug Administration, Office of
Combination Products, Office of Special Medical Programs Office of the Commissioner
“Classification of Products as Drugs and Devices & Additional Product Classification Issues:
Guidance for Industry and FDA Staff” September 2017.
https://www.fda.gov/media/80384/download

50. Fliesler N. “Capturing SARS-CoV-2’s shape-shifting spike protein” Posted July 21, 2020.
Boston Children’s Hospital Website Visited June 29, 2023.
https://answers.childrenshospital.org/sars-cov-2-spike-protein/

51. Moderna Patent. Bancel S, Chakraborty T, Fougorelles A, “Modified polynucleotides for the
production of secreted proteins” US9828416B2: November 28,
2017. https://patents.google.com/patent/US9828416B2/en Also accessed February
2022 https://www.modernatx.com/sites/default/files/US10703789.pdf

52. Rawati J, Kumar V, Ahlwat P, et al. “Current Trends on the Effects of Metal-Based
Nanoparticles on Microbial Ecology” Applied Biochemistry and Biotechnology; Feb 17, 2023.
https://doi.org/10.1007/s12010-023-04386-0

53. Wang R, Song B, Wu J, et al. “Potential adverse effects of nanoparticles on the reproductive
system” Int Jrnl of Nanomedicine: 2018:13 8487–8506
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294055/pdf/ijn-13-8487.pdf

54. Handy RD and Shaw BJ. “Toxic effects of nanoparticles and nanomaterials: Implications for
public health, risk assessment and the public perception of nanotechnology” Health, Risk, &
Society; Volume 9;2007. https://doi.org/10.1080/13698570701306807

55. Cupaioli FA, Zucca FA, Boraschi D, Zecca L. Engineered nanoparticles. How brain friendly
is this new guest? Prog Neurobiol. 2014 Aug-Sep;119-120:20-38. doi:
10.1016/j.pneurobio.2014.05.002. Epub 2014 May 10. PMID: 24820405.
https://pubmed.ncbi.nlm.nih.gov/24820405/

56. Pfizer. Confidential. “APPENDIX 2.2: Cumulative and Interval Summary Tabulation of
Serious and Non-Serious Adverse Reactions from Post-Marketing Data Sources, BNT162B2.”
Data collected from December of 2020 through June 18, 2022.
https://www.globalresearch.ca/wp-content/uploads/2023/05/pfizer-report.pdf

57. Center for Disease Control (CDC). “VAERS COVID Vaccine Adverse Event Reports.” US
Data. June 16, 2023. https://openvaers.com/covid-data

58. Lazarus Ross, MBBS, MPH, MMed, GDCompSci, Michael Klompas, MD, MPH.
“Electronic Support for Public Health–Vaccine Adverse Event Reporting System
(ESP:VAERS).” Prepared by Harvard Pilgrim Health Care, Inc. for U.S. Department of Health
and Human Services. Inclusive dates: 12/01/07 - 09/30/10
https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-
2011.pdf

59. United States Department of Defense, Joint Artificial Intelligence Center (JAIC), Humetrix
data; “Effectiveness of mRNA COVID-19 Vaccines Against the Delta Variant Among 5.6M
Medicare Beneficiaries 65 Years and Older.” September 28,
2021. https://www.humetrix.com/powerpoint-vaccine.html

60. Link-Gelles, Ruth, PhD, MPHLCDR, US Public Health Service COVID-19 Vaccine
Effectiveness Program Lead Centers for Disease Control and Prevention. “COVID-19 Vaccine
Effectiveness Updates.” June 15 2023. https://www.fda.gov/media/169536/download

61. CDC V-SAFE Database. Accessed June 28, 2023. https://vaxxsafedata.com/about-us/

62. FL SG Dr. Josepha Ladapo.”Exploring the relationship between all-cause and cardiac-
related mortality following COVID-19 vaccination or infection in Florida residents: a self-
controlled case series study” Oct 2022. https://floridahealthcovid19.gov/wp-
content/uploads/2022/10/20221007-guidance-mrna-covid19-vaccines-analysis.pdf

63. Paknahad MH, Yancheshmeh FB, Soleimani A. Cardiovascular complications of COVID-19

vaccines: A review of case-report and case-series studies. Heart Lung. 2023 May-Jun;59:173-
180. doi: 10.1016/j.hrtlng.2023.02.003. Epub 2023 Feb 8. PMID: 36842342; PMCID:
PMC9905103. https://pubmed.ncbi.nlm.nih.gov/36842342/
64. AHA “Coronavirus spike protein activated natural immune response, damaged heart muscle
cells” American Heart Association Basic Cardiovascular Sciences Meeting – Presentation:
P3119. July 25, 2022. https://newsroom.heart.org/news/coronavirus-spike-protein-activated-
natural-immune-response-damaged-heart-muscle-
cells#:~:text=“Our%20data%20show%20that%20the,their%20own%20natural%20immune%20
machinery

65. Hansen T, Titze U, Kulamadayil-Heidenreich NSA, Glombitza S, Tebbe JJ, Röcken C,

Schulz B, Weise M, Wilkens L. First case of postmortem study in a patient vaccinated against
SARS-CoV-2. Int J Infect Dis. 2021 Jun;107:172-175. doi:10.1016/j.ijid.2021.04.053. Epub
2021 Apr 16. PMID: 33872783; PMCID: PMC8051011.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051011/

66. Acuitas Therapeutics. A Tissue Distribution Study of a [3H]-Labelled Lipid Nanoparticle-

mRNA Formulation Containing ALC-0315 and ALC-0159 Following Intramuscular
Administration in Wistar Han Rats. Test Facility Study No. 185350 Sponsor Reference No.
ALC-NC-0552. Nov 9, 2020. https://phmpt.org/wp-
content/uploads/2022/03/125742_S1_M4_4223_185350.pdf

67. Pfizer Inc. Japan. “SARS-CoV-2 mRNA Vaccine (BNT162, PF-07302048) Luciferase
RNA-encapsulated LNP administered intravenously to Wistar Han rats at a dose of 1 mg
RNA/kg. Plasma and Liver Concentrations of ALC-0315 and ALC-0159”

68. Society of Actuators (SoA) Research Institute. “Group Life COVID-19 Mortality Survey
Report” Aug 2022. https://www.soa.org/4a368a/globalassets/assets/files/resources/research-
report/2022/group-life-covid-19-mortality-03-2022-report.pdf

69. The White House. “FACT SHEET: President Biden to Announce Goal to Administer at
Least One Vaccine Shot to 70% of the U.S. Adult Population by July 4th.” WH Statement made
on May 4, 2021. https://www.whitehouse.gov/briefing-room/statements-
releases/2021/05/04/fact-sheet-president-biden-to-announce-goal-to-administer-at-least-one-
vaccine-shot-to-70-of-the-u-s-adult-population-by-july-4th/

70. CDC Data submitted to the OECD (Organization for Economic Cooperation and
Development) Accessed June 1, 2023. https://stats.oecd.org/index.aspx?queryid=104676#
71. Swart N. “Pfizer documents, official government data confirm: .75m vaccine deaths in 2022,
critical infertility” Biz News. Nov 23, 2022. https://www.biznews.com/health/2022/11/23/pfizer-
vaccine-deaths

72. Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proc
Natl Acad Sci USA. 1989 Aug;86(16):6077-81. doi: 10.1073/pnas.86.16.6077. PMC297778.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC297778/

73. Malone RW, Felgner P, Wolff J, et al. “DELIVERY OF EXOGENOUSDNA SEQUENCES

IN A MAMMAL” US5,580,859; Dec 9, 1996.
https://patentimages.storage.googleapis.com/6f/65/07/e39a6bf6d18e9d/US5580859.pdf

74. CDC “Historical information as RotaShield® was taken off U.S. market in 1999”CDC
website visited June 29, 2023. https://www.cdc.gov/vaccines/vpd-vac/rotavirus/vac-rotashield-
historical.htm#:~:text=The%20U.S.%20Advisory%20Committee%20on,between%20the%20vac
cine%20and%20intussusception.

75. CDC “Monitoring Vaccine Effectiveness.” CDC COVID-19 website visited June 29, 2023.
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/how-cdc-monitors.html

76. NIH Patent for “Vaccine Nanotechnology” US 9,539,210 B2 Jan 10, 2017.
https://patentimages.storage.googleapis.com/29/d1/ca/18013ced0621f0/US9539210.pdf

77. US Title 18 – Crimes and Criminal Procedures, Chapter 10 – Biological Weapons, §175.
Prohibitions with respect to biological weapons
https://uscode.house.gov/view.xhtml?path=/prelim@title18/part1/chapter10&edition=prelim

78. FL State Title XLVI – Crimes, Chapter 790 – Weapons and Firearms, SECTION
166Manufacture, possession, sale, delivery, display, use, or attempted or threatened use of a
weapon of mass destruction or hoax weapon of mass destruction prohibited; definitions;
penalties. https://m.flsenate.gov/Statutes/790.166

79. Schmeling M, Manniche V, Hansen PR. “Batch-dependent safety of the BNT162b2 mRNA
COVID-19 vaccine” European Journal of Clinical Investigation. March 30, 2023.
https://doi.org/10.1111/eci.13998
80. European Medical Agency. “Safety of COVID-19
vaccines.” https://www.ema.europa.eu/en/human-regulatory/overview/public-health-
threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/safety-covid-19-
vaccines Assessed January 6, 2023.

81. European Directorate for the Quality of Medicines and Healthcare. “EDQM initiatives in the
context of COVID-19 vaccines and therapies.” https://www.edqm.eu/en/edqm-initiatives-in-the-
context-of-covid-19-vaccines-and-therapies Assessed January 6, 2023.

82. Banoun H. “mRNA: Vaccine or Gene Therapy? The Safety Regulatory

Issues.” International Journal of Molecular Sciences. 2023; 24(13):10514.
https://doi.org/10.3390/ijms241310514